Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To Purchase An Aggregate Of Up To 39,473,688 Of Lineage's Common Shares At A Combined Purchase Price Of $0.76 Per Common Share And Accompanying Common Warrant
lineage cell therapeutics與特定的機構投資者和Broadwood Partners, L.P.簽訂了最終協議，以購買和銷售高達39,473,688股lineage普通股和相應的認股權證，購買價格爲每股0.76美元，並附帶普通股認股權證
$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants
3,000萬美元的初始費用，全額行使臨床里程碑關聯普通股認股權可獲得高達3,600萬美元的綜合毛收益
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage's common shares at a combined purchase price of $0.76 per common share and accompanying common warrant, in a registered direct offering. Each common warrant will be exercisable for one common share at an exercise price of $0.91 per common share and will be exercisable commencing six months following their date of issuance and will expire on the earlier of (a) the three-year anniversary of the initial exercise date, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to the initial exercise date of the common warrants, the 90th day following the initial exercise date. However, the common warrants that may be issued to Broadwood will not be exercisable until the later of (i) their date of issuance, which will be the date shareholder approval is obtained, and (ii) the six-month anniversary of the date of issuance of the common warrants to the unaffiliated institutional investors in the offering.
生物技術公司lineage cell therapeutics, Inc. (NYSE美國交易所和TASE：LCTX)是一家臨床階段的公司，致力於爲未滿足的醫療需求開發異基因細胞療法，今日宣佈與特定以醫療爲重點的機構投資者和Broadwood Partners, L.P.（「Broadwood」）達成最終協議，由Neal Bradsher的關聯公司Broadwood購買及出售高達39，473，688股lineage普通股和相應認股權證（「普通認股權證」），購買價格爲每股0.76美元，並附帶普通股認股權證，在一次公開直接發行。每個普通認股權證可按行權價格0.91美元行使一股普通股，自發行之日起六個月後行使，於最早的一下日期到期：(a)初始行權日期三週年日期，和(b)正面向普騰（又名RG6501）推進至多中心2或3期臨床試驗，幷包括對照組或比較組的公開意圖的日期，或者如果該公開意圖日期早於普通認股權證的初始行權日期，則是普通認股權證的初始行權日期之後第90天。然而，可能發行給Broadwood的普通認股權證直至後者行使，即(i) 股東批准日的發行日期和(ii）發行給發行的非關聯機構投資者普通認股權證之日起六個月週年日期之後，才可行使。
H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 作爲本次發行的獨家配售代理。
譯文內容由第三人軟體翻譯。
